relugolix + abiraterone + methylprednisolone

This is a **combination therapy** composed of relugolix (an oral non-peptide gonadotropin-releasing hormone [GnRH] receptor antagonist used for androgen deprivation), abiraterone (a selective and irreversible inhibitor of CYP17A1 enzyme and thereby a testosterone synthesis inhibitor), and methylprednisolone (a synthetic corticosteroid that suppresses inflammation and compensates for the mineralocorticoid excess resulting from abiraterone administration)[2][3][5]. - **Mechanisms of action:** - **Relugolix** blocks the GnRH receptor leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in lower testosterone production. - **Abiraterone** inhibits CYP17A1, reducing androgen synthesis in testes, adrenals, and prostate tumors. - **Methylprednisolone** acts as a glucocorticoid for anti-inflammatory and mineralocorticoid compensation[2][3]. - This combination is under investigation to improve clinical outcomes in men with **advanced prostate cancer**, including metastatic castration-sensitive and castration-resistant subtypes. - Clinical trials show that the combination maintains castrate testosterone levels and has a safety/tolerability profile consistent with the individual agents[2][3][5].